475 assets in Plasma Cell Myeloma

Therapeutic assets addressing Plasma Cell Myeloma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Dabrafenib Plasma Cell Myeloma	Cancer Research UK	P2/3	CCC (52)
Forimtamig Plasma Cell Myeloma	Hoffmann-La Roche	P1/2	CCC (52)
Nadravaleucel Plasma Cell Myeloma	David Wald	P1/2	CCC (52)
Nepenthe Plasma Cell Myeloma	University Hospital Heidelberg	P3	CCC (52)
Infliximab Plasma Cell Myeloma	Naresh Bumma	P2	CCC (51)
Anitocabtagene-Autoleucel Plasma Cell Myeloma	Kite, A Gilead Company	P2	CCC (50)
Bcd-264 Plasma Cell Myeloma	Biocad	P3	CCC (50)
Boclatixafortide Plasma Cell Myeloma	University Health Network, Toronto	P2	CCC (50)
Catequentinib Plasma Cell Myeloma	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (50)
Cemsidomide Plasma Cell Myeloma	C4 Therapeutics, Inc.	P2	CCC (50)
Ciltacabtagene Autoleucel Plasma Cell Myeloma	Medical College of Wisconsin	P2	CCC (50)
Colchicinum Plasma Cell Myeloma	Affiliated Hospital of Nantong University	P3	CCC (50)
Elraglusib Plasma Cell Myeloma	Actuate Therapeutics Inc.	P2	CCC (50)
Equecabtagene Autoleucel Plasma Cell Myeloma	Nanjing IASO Biotechnology Co., Ltd.	P3	CCC (50)
Grastofil Plasma Cell Myeloma	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	P3	CCC (50)
Human Bcma Targeted T Cells Plasma Cell Myeloma	Hrain Biotechnology Co., Ltd.	P2	CCC (50)
Idecabtagene Vicleucel Plasma Cell Myeloma	St. Olavs Hospital	P3	CCC (50)
Inobrodib Plasma Cell Myeloma	CellCentric Ltd.	P2	CCC (50)
Iopofosine (¹³¹I) Plasma Cell Myeloma	Cellectar Biosciences, Inc.	P2	CCC (50)
Lapelga Plasma Cell Myeloma	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	P3	CCC (50)
Moderna Bivalent Mrna Vaccine Plasma Cell Myeloma	Monash University	P3	CCC (50)
Narlumosbart Plasma Cell Myeloma	RenJi Hospital	P3	CCC (50)
Olanzapine Plasma Cell Myeloma	The Affiliated People's Hospital of Ningbo University	P3	CCC (50)
Olaparib Plasma Cell Myeloma	Medical College of Wisconsin	P2	CCC (50)
Oxycodone Plasma Cell Myeloma	Memorial Sloan Kettering Cancer Center	P3	CCC (50)
Oxycodone Hydrochloride, Hydrocodone- Plasma Cell Myeloma	St. Louis University	P3	CCC (50)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493 Plasma Cell Myeloma	Multiple Myeloma Research Consortium	P2	CCC (50)
Pertuzumab Plasma Cell Myeloma	OHSU Knight Cancer Institute	P2	CCC (50)
Pfizer Bivalent Covid-19 Vaccine Plasma Cell Myeloma	Monash University	P3	CCC (50)
Regorafenib Plasma Cell Myeloma	OHSU Knight Cancer Institute	P2	CCC (50)
Relatlimab Plasma Cell Myeloma	National Cancer Institute (NCI)	P2	CCC (50)
Trastuzumab Emtansine Plasma Cell Myeloma	OHSU Knight Cancer Institute	P2	CCC (50)
Tropisetron Plasma Cell Myeloma	The Affiliated People's Hospital of Ningbo University	P3	CCC (50)
Tucidinostat Plasma Cell Myeloma	The First Affiliated Hospital of Soochow University	P2	CCC (50)
Vismodegib Plasma Cell Myeloma	OHSU Knight Cancer Institute	P2	CCC (50)
gc012f Plasma Cell Myeloma	Gracell Biotechnologies (Shanghai) Co., Ltd.	P1/2	CCC (49)
Moderna Covid-19 Vaccine Rna Plasma Cell Myeloma	Barbara Ann Karmanos Cancer Institute	P2	CCC (49)
Allogeneic Anti-Ny-Eso-1-Tcr-Il-15-Transduced Cord Blood-Derived Natural Killer Cells Plasma Cell Myeloma	M.D. Anderson Cancer Center	P1/2	CCC (48)
Binimetinib Plasma Cell Myeloma	University of Heidelberg Medical Center	P2	CCC (48)
C-Car088 Plasma Cell Myeloma	Institute of Hematology & Blood Diseases Hospital, China	P1/2	CCC (48)
CD47/SIRPA-BLOCKING AGENT ALX148 Plasma Cell Myeloma	Sanofi	P1/2	CCC (48)
Cytokine-Treated Veto Cells Plasma Cell Myeloma	M.D. Anderson Cancer Center	P1/2	CCC (48)
Descartes-08 Plasma Cell Myeloma	Cartesian Therapeutics	P2	CCC (48)
Fexagratinib Plasma Cell Myeloma	National Cancer Institute (NCI)	P2	CCC (48)
Ganciclovir Plasma Cell Myeloma	City of Hope Medical Center	P2	CCC (48)
Gpc-100 Plasma Cell Myeloma	GPCR Therapeutics, Inc.	P2	CCC (48)
hul001 Plasma Cell Myeloma	HuniLife Biotechnology, Inc.	P1/2	CCC (48)
Icp-490 Plasma Cell Myeloma	Beijing InnoCare Pharma Tech Co., Ltd.	P1/2	CCC (48)
Linperlisib Plasma Cell Myeloma	Fuling Zhou	P1/2	CCC (48)
Narazaciclib Plasma Cell Myeloma	Adriana Rossi	P1/2	CCC (48)

Showing 151 to 200 of 475 assets

PreviousPage 4 of 10Next